Search

everythinglearnresearchcommunity

for

Search:↓

IL-17 inhibitors are more effective than methotrexate in preventing psoriatic arthritis in psoriasis patients.

IL-1 alpha stops hair follicle growth and hair production.

ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.

TNF-α blockers and IL inhibitors improve symptoms in most patients with severe scalp condition, but more research is needed.

A protein called IL-36γ causes skin side effects from certain cancer treatments when combined with a common skin bacteria.

Biologics and JAK inhibitors may improve treatment for scarring alopecias.

TNFα inhibitors are effective and well-tolerated for treating severe scalp cellulitis.

Blocking IL-8 can reduce skin rashes from cancer treatment.

Blocking EGFR can cause skin inflammation by disrupting IL-1 signaling.

Ruxolitinib may help treat hair loss by reducing inflammation, promoting hair growth signals, and protecting hair follicle immunity.

Erlotinib causes skin inflammation through IL-1, which can be reduced by anakinra.

Interleukin levels are higher in alopecia areata patients but don't predict disease severity or duration.

EGFRi/MEKi treatments cause hair follicles to lose some immune protection, leading to inflammation.

Blocking EGFR in skin cells doesn't majorly increase inflammation markers.

A man developed skin lesions as a side effect of a gamma secretase inhibitor used for treating a tumor.

Two new IRAK4-inhibitors effectively reduced skin inflammation and immune response markers in healthy volunteers.

IL-15 helps maintain hair growth and protects the immune status of hair follicles.

Bacteria can help skin regenerate through a process called IL-1β signaling.

Melanogenesis inhibitors like kojic acid and niacinamide can reduce inflammation and pigment production in skin cells.

Upadacitinib successfully regrew hair in a child with alopecia universalis and specific genetic mutations.

ATR04-484 ointment shows promise for treating skin issues from cancer therapies.

The inhibitor DPP can promote hair growth.

IL-4 and IL-13 might play a role in a type of hair loss similar to alopecia areata.

Ritlecitinib may help treat alopecia areata by protecting hair follicles.

Blocking TYK2 might be a new way to treat hair loss from alopecia areata.

Inhibiting TYK2 can restore hair growth in alopecia areata.

IL-17 inhibitors for psoriasis may cause unexpected hair loss.

Ustekinumab effectively treated psoriasis and ulcerative colitis in a teen after infliximab caused complications.

TNF-alpha inhibitors can cause various immune-related skin issues.